Sentences with phrase «received docetaxel»

A large trial showing that men with newly diagnosed, advanced prostate cancer lived ten months longer, on average, when they received docetaxel chemotherapy along with standard hormone therapy

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

The men receiving docetaxel had an average of 32.7 months before the cancer progressed by worsening scan results or symptoms, compared to 19.8 months for hormone therapy alone.

A total of 28.9 % of patients receiving docetaxel had not progressed after 6 months, compared with 16.9 % of erlotinib patients.

Not exact matches

Researchers randomly selected 135 patients to receive nivolumab, sold under the name Opdivo, and 137 others to receive the chemotherapy drug docetaxel.

Patients were randomised 1:1 to receive therapy with ceritinib or chemotherapy (pemetrexed or docetaxel).

It included 790 patients (median age of 63 years) who were enrolled and randomized from July 2006 to November 2012 to receive either ADT plus docetaxel every three weeks for six cycles or ADT alone.

In the ADT - plus - docetaxel group, 45 patients whose disease progressed received additional docetaxel.

Patients received 3 cycles of docetaxel at either 80 mg / m2 or 100 mg / m2 and trastuzumab three times a week followed by 3 cycles of chemotherapy.

Disease - free survival was similar in the 9 - week and 12 - month arms among those patients who received 100 mg / m2 docetaxel.

In contrast, among those who received 80 mg / m2 docetaxel, 12 months of trastuzumab had superior disease - free survival.

The BMS trial, called Checkpoint - 017, randomized 272 patients to receive either nivolumab intravenously every two weeks or the chemotherapy drug docetaxel intravenously every three weeks.

The other group will receive LY2181308 alongside docetaxel.

Inclusion Criteria: • The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant and adjuvant therapies will not be considered as a prior line of therapy) for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.

• The participant has received prior treatment with gemcitabine or docetaxel.